MYB and benign spiradenoma: We will review, in alphabetical order, adenoid cystic carcinoma (NFIB and MYB fusion), mixed tumor (PLAG1 fusion), cylindroma and spiradenoma (NF-κB activation through CYLD inactivation or ALKP1 hotspot mutation), hidradenoma (CRTC1/3 and MAML2 fusion), myoepithelioma (EWSR1 and FUS fusion), poroma (YAP1 and NUTM1 fusion), secretory carcinoma (ETV6 and NTRK3 fusion), tubular adenoma and syringocystadenoma papilliferum (HRAS and BRAF activating mutations).